| H2 antagonist | <pharmacology> A class of anti-ulcer medication which work through the inhibition of basal and nocturnal gastric acid secretion by competitive inhibition of the action of histamine at histamine H2 receptor sites on the parietal cells. Drugs of this type block gastric acid secretion and are therefore clinically useful in treating duodenal ulcers. Examples include cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid) and ranitidine (Zantac). (27 Sep 1997) |
|---|---|
| H2 blocker | <pharmacology> A class of anti-ulcer medication which work through the inhibition of basal and nocturnal gastric acid secretion by competitive inhibition of the action of histamine at histamine H2 receptor sites on the parietal cells. Drugs of this type block gastric acid secretion and are therefore clinically useful in treating duodenal ulcers. Examples include cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid) and ranitidine (Zantac). (27 Sep 1997) |
| H2 histocompatibility | <immunology> The ability of a tissue to be grafted from a donor to a host, without the host's immune system attacking the grafted tissue. The chances of H2 histocompatibility is determined by how well the tissue proteins (cell surface glycoproteins in the tissue, to be specific) match between donor and host. (09 Oct 1997) |
| H2Q | Symbol for ubiquinol. (05 Mar 2000) |